N-Propargylpiperidines with naphthalene-2-carboxamide
or naphthalene-2-sulfonamide
moieties: Potential multifunctional anti-Alzheimer’s agents
10.1016/j.bmc.2016.11.032 · doi-reference
Stereoselective activity
of 1-propargyl-4-styrylpiperidine-like analogues
that can discriminate between monoamine oxidase isoforms A and B
10.1021/acs.jmedchem.9b01886 · doi-reference
Rasagiline
protects against alpha-synuclein
induced sensitivity to oxidative stress in dopaminergic cells
10.1016/j.neuint.2010.06.017 · doi-reference
Rotenone, Paraquat, and Parkinson’s Disease
10.1289/ehp.1002839 · doi-reference
Chapter 15
- Paraquat-induced Neurodegeneration: a Model of Parkinson’s
Disease Risk Factors
10.1016/b978-0-12-374028-1.00015-4 · doi-reference
Neurotoxicity
of ″ecstasy″ and its metabolites
in human dopaminergic differentiated SH-SY5Y cells
10.1016/j.toxlet.2012.11.015 · doi-reference
The mixture of ″ecstasy″
and its metabolites is toxic to human SH-SY5Y differentiated cells
at in vivo relevant concentrations
10.1007/s00204-013-1120-7 · doi-reference
Rearrangements of
N-oxides. A novel synthesis of pyridyl
carbinols and aldehydes
10.1021/ja01634a026 · doi-reference
The rearrangement
of substituted pyridine N-oxides with acetic anhydride1.2
10.1021/jo01061a037 · doi-reference
Iron-catalyzed
oxidative functionalization of C(sp3)–H bonds under
bromide-synergized mild conditions
10.1039/c9cc03939b · doi-reference
Development
of a flow photochemical
aerobic oxidation of benzylic C–H bonds
10.1021/acs.orglett.8b00540 · doi-reference
Electrochemical
benzylic
oxidation of C–H bonds
10.1039/c8cc08768g · doi-reference
Selective
electrochemical oxygenation of alkylarenes to carbonyls
10.1021/acs.orglett.1c02651 · doi-reference
Superacid-catalyzed intramolecular
cyclization reaction of arylcyanopropionate: Geminal substitution
effect on superelectrophilicity
10.1021/jo800674h · doi-reference
Synthesis of 6,7-dihydro-5H-cyclopenta[b]pyridin-5-one analogues
through manganese-catalyzed oxidation of
the CH2 adjacent to pyridine moiety in water
10.1039/c4gc02471k · doi-reference
Dopamine autoreceptor
agonists as
potential antipsychotics. 3. 6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine
10.1021/jm00113a010 · doi-reference
Performance
of chiral tetracarbonylmolybdenum
pyrindanyl amine complexes in catalytic olefin epoxidation
10.1016/j.jorganchem.2018.01.003 · doi-reference
Receptor-based virtual ligand screening
for the identification
of novel CDC25 phosphatase inhibitors
10.1021/ci700313e · doi-reference
5-Substituted [1]pyrindine
derivatives with antiproliferative activity
10.1016/j.ejmech.2009.11.028 · doi-reference
Synthesis and evaluation of a series
of aminocyanopyridines as antimicrobial agents
10.1007/s00044-009-9273-x · doi-reference
Practical
asymmetric synthesis of a selective endothelin a receptor (ETA) antagonist
10.1021/ol016601s · doi-reference
Cefpirome. A review of its antibacterial
activity,
pharmacokinetic properties and clinical efficacy in the treatment
of severe nosocomial infections and febrile neutropenia
10.2165/00003495-199754010-00013 · doi-reference
Synthesis
and characterization of 1-pyrindane derivatives as rasagiline analogues
10.1016/j.cdc.2016.10.001 · doi-reference
Synthesis of new propargylated 1-pyrindane
derivatives as rasagiline analogues
10.1055/s-0032-1318492 · doi-reference
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
10.3389/fphar.2016.00340 · doi-reference
Binding of rasagiline-related inhibitors
to human monoamine oxidases: A kinetic and crystallographic analysis
10.1021/jm0506266 · doi-reference
Regulation
of Bcl-2
family proteins, neurotrophic factors, and APP processing in the neurorescue
activity of propargylamine
10.1096/fj.05-3794fje · doi-reference
Anti-apoptotic
function of propargylamine inhibitors of type-B monoamine oxidase
10.1163/156856003765764344 · doi-reference
Novel neuroprotective
anti-Alzheimer drugs with anti-depressant
activity derived from the anti-Parkinson drug, rasagiline
10.1016/s0047-6374(01)00391-8 · doi-reference
Rasagiline
10.2165/00002512-200522010-00006 · doi-reference
The importance
of
propargylamine moiety in the anti-Parkinson drug rasagiline and its
derivatives in MAPK-dependent amyloid precursor protein processing
10.1096/fj.03-0078fje · doi-reference
Rasagiline combined
with levodopa therapy versus levodopa monotherapy
for patients with Parkinson’s disease: A systematic review
10.1007/s10072-019-04050-8 · doi-reference
Antiapoptotic
properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its
optical (S)-isomer, TV1022
10.1111/j.1749-6632.2001.tb03641.x · doi-reference
Neurotoxins induce
apoptosis in dopamine neurons: protection by N-propargylamine-1(R)-
and (S)-aminoindan, rasagiline and TV1022
10.1007/978-3-7091-6301-6_11 · doi-reference
Rasagiline: A
novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective
activity
10.1016/j.pneurobio.2010.06.008 · doi-reference
Effect
of long-term treatment with rasagiline on cognitive deficits and related
molecular cascades in aged mice
10.1016/j.neurobiolaging.2015.05.009 · doi-reference
Mitochondrial permeability transition mediates apoptosis induced
by N-methyl(R)salsolinol, an endogenous
neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan
10.1046/j.1471-4159.2002.01047.x · doi-reference
Rasagiline
and selegiline suppress calcium efflux from mitochondria by PK11195-induced
opening of mitochondrial permeability transition pore: A novel anti-apoptotic
function for neuroprotection
10.1007/s00702-015-1398-0 · doi-reference
Neuroprotective and neuro-restorative effects of minocycline
and rasagiline in a zebrafish 6-hydroxydopamine model of Parkinson’s
disease
10.1016/j.neuroscience.2017.10.018 · doi-reference
Rasagiline:
Neurodegeneration, neuroprotection,
and mitochondrial permeability transition
10.1002/jnr.20350 · doi-reference
